News
Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of $23.00. Discover outperforming stocks and invest smarter ...
Morgan Stanley lowered the firm’s price target on Moderna (MRNA) to $32 from $39 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
